Composition For Treating Or Preventing Liver Cancer
AssigneeSeoul National University R&Db Foundation
InventorsGuhung Jung, Eunkyong Ko, Yoon Jun Kim
Life of this patent
Estimating the term…
Abstract
The present application relates to a pharmaceutical composition containing compound 5-fluoro-3-phenyl-2-[(15)-1-(7H-purin-6-ylamino)propyl]-4-3H)-quinazolinone, and a pharmaceutically acceptable salt thereof for preventing and treating liver cancer, and the composition of the present application inhibits ROS-PI3K-AKT-TERT signal transduction, and thus can be favorably used in the treatment of a liver cell cancer, in which a protein involved in the signal transduction is overexpressed, especially, advanced liver cell cancer.
Claims14
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for suppressing expression of PI3K isotype p110δ in liver cancer cells including treating the liver cancer cells with 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone or a salt thereof.
A method for inhibiting ROS-PI3K-AKT-TERT signal transduction pathway in liver cancer cells including treating the liver cancer cells with 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone or a salt thereof.
A method for treating hepatocellular carcinoma including administering a pharmaceutically effective amount of the compound 5 -fluoro-3 -phenyl-2- [(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone or a pharmaceutically acceptable salt thereof to a subject who is in need of a treatment of hepatocellular carcinoma.
Dependencies are inferred from the claim text.